Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDP-124 · 2 trials · 1 indication
Investigator Global Assessment (IGA) was determined based on evaluator-blinded evaluations of the inflammatory signs of atopic dermatitis. Evaluations were scored using a 5-point scale from clear (0) to severe (4), with higher numbers indicating worse scores.
| Arm | Type | Description |
|---|---|---|
| IDP-124 Lotion | EXPERIMENTAL | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | ACTIVE_COMPARATOR | IDP-124 Vehicle Lotion, twice-daily application |
| Name | Type | Description |
|---|---|---|
| IDP-124 Lotion | DRUG | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | DRUG | IDP-124 Vehicle Lotion, twice-daily application |
Inclusion Criteria: * Male or female at least 2 years of age and older * Written and verbal informed consent must be obtained; subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent durin...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
IDP-124 is an investigational small molecule being developed for the treatment of moderate to severe atopic dermatitis in pediatric and adult subjects. It is formulated as a lotion and is currently in Phase 3 clinical development. The drug has not been approved by the FDA and remains under investigation.
IDP-124 is being developed by Bausch Health Companies Inc. (NYSE: BHC). The company is conducting Phase 3 clinical trials to evaluate the efficacy and safety of IDP-124 lotion for the treatment of moderate to severe atopic dermatitis in pediatric and adult subjects.
IDP-124 is in Phase 3 clinical development. Two Phase 3 trials have been completed, with a total enrollment of 666 subjects. The drug is investigational and has not been approved by the FDA for any use.
IDP-124 has been studied in two completed Phase 3 clinical trials: NCT03002571 with 338 participants and NCT03058783 with 328 participants. Both trials evaluated the efficacy and safety of IDP-124 lotion for moderate to severe atopic dermatitis in pediatric and adult subjects in the United States.
No, IDP-124 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. Two Phase 3 trials have been completed, but the drug has not received regulatory approval for the treatment of atopic dermatitis or any other condition.